MOC Machinations

The changing landscape of MOC Knowledge Check-Ins and how the American Society of Hematology continues pursuing a pragmatic approach to the MOC process.  The past five years have been turbulent for the American Board of...

Online Exclusives

MD Anderson Fined $4.3 Million for HIPAA Violation

An administrative judge within the U.S. Department of Health and Human Services (HHS) has ruled that the University of Texas MD Anderson Cancer Center...

CMS Cancels Agreement With Novartis to Pay for CAR T-Cell Treatment

The U.S. Centers for Medicare and Medicaid Services (CMS) has ended a proposed “outcomes-based” agreement to pay for tisagenlecleucel, a chimeric antigen receptor (CAR)...

News

From the Blood Journals

Psychiatric Comorbidities of Myeloma Lead to High Health-Care Costs

Many patients with multiple myeloma (MM) have a high risk for developing psychiatric comorbidities and, according to a study published in Blood Advances, managing...
WIB_icon

Treating MPNs With JAK1/2 Inhibitors Increases Risks for B-Cell Lymphomas

JAK1/2 inhibitors have been used as standard and experimental treatment of myeloproliferative neoplasms (MPNs) for years, but according to research published in Blood, their...

Multimedia

Pulling Back the Curtain: Allison Rosenthal, DO

Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...
video

Enhancing Ibrutinib With Rituximab in Waldenström Macroglobulinemia

Combining ibrutinib with rituximab led to longer progression-free survival, compared with ibrutinib alone, in patients with Waldenström macroglobulinemia. Meletios Dimopoulos, MD, shares results from...

On Location

Axicabtagene Ciloleucel Moves to Acute Lymphocytic Leukemia

Axicabtagene ciloleucel, which in October 2017 became the first chimeric antigen receptor (CAR) T-cell therapy...

Moxetumomab Pasudotox: An Alternative to Chemotherapy in Hairy Cell Leukemia

In a pivotal phase III clinical trial of moxetumomab pasudotox in patients with relapsed/refractory hairy...

Phase III BFORE Trial: Bosutinib Beats Imatinib for Frontline CML Treatment

Patients with previously untreated chronic myeloid leukemia (CML) who received bosutinib were more likely than...

bb2121: Is CAR T-Cell Therapy Moving to Myeloma?

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of acute lymphocytic leukemia and...

Acalabrutinib Induces Durable Response in Patients With Waldenström Macroglobulinemia

In a phase II study of patients with Waldenström macroglobulinemia (WM), treatment with the highly...

Evaluating FT-2102 in IDH1-Mutated AML or MDS

According to interim data from a first-in-human phase I trial, treatment with FT-2102, a selective...

Latest Headlines

Advertisement

ASH Directions

A Call to Action on Hematology and Aging, ASH Clinical News Wins Award of...

A Call to Action on Hematology and Aging The Journal of Geriatric Oncology has published a report by lead author Ashley E. Rosko, MD, from...

ASH Choosing Wisely Item Makes the ABIM Top 12, Celebrating World Sickle Cell Day,...

ASH Choosing Wisely Recommendation Makes the ABIM Top 12 The Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine (ABIM) Foundation, encourages clinicians...

Sign up for our
eNewsletter!

American Cancer Society Awards $2.6 Million for Immunotherapy Research, and more

Remembering Past ASH President George Stamatoyannopoulos (1934 - 2018) George Stamatoyannopoulos, MD, DrSci, a professor of medical genetics at the University of Washington who pioneered...

Vijay Sankaran Receives Weill Cornell’s Children’s Health Research Award, Scripps Researchers Receive Nearly $3...

Remembering Frank “Len” Johnson (1945 - 2017)  Frank Leonard “Len” Johnson, MD, a pediatric hematologist/oncologist, passed away on December 24, 2017, after a brief illness. Growing...

ACS Grants $47 Million in Funding, Stand Up to Cancer Announces Innovation Awards, and...

Lawrence B. Gardner, MD, an assistant professor of medicine and pharmacology at New York University (NYU) Langone Health, died on March 27 at age...

MOC Machinations

The changing landscape of MOC Knowledge Check-Ins and how the American Society of Hematology continues pursuing a pragmatic approach to the MOC process.  The past...

Leveling the Playing Field: Can We Achieve Gender Equality in Medicine?

When Stephanie Abbuhl, MD, professor of emergency medicine at the University of Pennsylvania Perelman School of Medicine, was growing up in the early 1960s,...

The Pharmacoeconomics of Oral and Self-Administered Cancer Treatments

Oral and patient-administered forms of chemotherapy have come a long way since the 1950s, when mercaptopurine and methotrexate were first approved by the U.S....